Partisan Management Group
VC Fund
Evergreen, United States
Partisan Management Group is a highly successful, early stage venture capital investor in medical device companies.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries Partisan Management Group invests in
MedicalHealth CareBiotechnologyMedical DevicePharmaceutical
Stages Partisan Management Group invests in
Funding RoundSeries ASeries BSeries DSeed
Countries Partisan Management Group invests in
United StatesIreland
Round sizes
Series A $6.1M–$30MSeries B $16M–$50M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6.1M–$30M
- Series B
- $16M–$50M
Investment Focus
Industry
- Medical 8 (32%)
- Health Care 8 (32%)
- Biotechnology 7 (28%)
- Medical Device 5 (20%)
- Pharmaceutical 3 (12%)
Stage
- Funding Round 4 (16%)
- Series A 3 (12%)
- Series B 3 (12%)
- Series D 3 (12%)
- Seed 2 (8%)
Country
- United States 10 (40%)
- Ireland 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Karen Cassidy
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Norman Weldon
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $50M / Series B / Oct 25, 2018 | ||
| Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $12.8M / Series D / Mar 03, 2017 | ||
| Ponce De Leon Pharmaceuticals is a privately financed development stage company, committed to the extension of human health span, endeavoring to offer more healthy years of living. In conjunction with the Buck Institute for Research on Aging, the Company has developed a formulation comprised of GRAS (Generally Regarded As Safe) components. Thisformulation has been shown to radically increase mean lifespan in the invertebrate model (C. Elegan), well beyond any previously published data on drugs or compounds. Testing has now begun at the Buck Institute in the mammalian model (mouse), and the Company hopes to have a patent pending product available to the public at the conclusion of those studies, or in about three years. | Seed / Jan 03, 2017 | ||
| Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $30M / Series A / Oct 05, 2016 | ||
| Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $15M / Series C / Dec 02, 2015 | ||
| Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | Venture - Series Unknown / Oct 20, 2015 | ||
| Preceptis Medical is a medical device manufacturer developing surgical tools that allow ear tube procedures to be performed with reduced pain and surgical time for the pediatric patient. Its pediatric surgical technology Hummingbird TTS offers an alternative to general anesthesia and minimizes surgical trauma during ear tube placement, enablingphysicians to use moderate sedation for routine ear tube procedures.Preceptis Medical was founded in 2011 and is headquartered in Maple Grove, Minnesota. | $976K / Convertible Note / Jun 10, 2015 | ||
| Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $34.3M / Series F / Apr 27, 2015 | ||
| Ponce De Leon Pharmaceuticals is a privately financed development stage company, committed to the extension of human health span, endeavoring to offer more healthy years of living. In conjunction with the Buck Institute for Research on Aging, the Company has developed a formulation comprised of GRAS (Generally Regarded As Safe) components. Thisformulation has been shown to radically increase mean lifespan in the invertebrate model (C. Elegan), well beyond any previously published data on drugs or compounds. Testing has now begun at the Buck Institute in the mammalian model (mouse), and the Company hopes to have a patent pending product available to the public at the conclusion of those studies, or in about three years. | Seed / Jun 25, 2014 | ||
| Preceptis Medical is a medical device manufacturer developing surgical tools that allow ear tube procedures to be performed with reduced pain and surgical time for the pediatric patient. Its pediatric surgical technology Hummingbird TTS offers an alternative to general anesthesia and minimizes surgical trauma during ear tube placement, enablingphysicians to use moderate sedation for routine ear tube procedures.Preceptis Medical was founded in 2011 and is headquartered in Maple Grove, Minnesota. | $4.4M / Venture - Series Unknown / Jan 31, 2014 | ||
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
48,825 investors
Biotech Investors
24,243 investors
Biotechnology Investors
21,493 investors
Medical Investors
21,329 investors
Medical Device Investors
12,476 investors
Health Care VC Funds
36,610 investors
Biotech VC Funds
20,947 investors
Biotechnology VC Funds
18,846 investors
Medical VC Funds
18,339 investors
FAQ
What does Partisan Management Group invest in?
Partisan Management Group invests primarily in Medical, Health Care and Biotechnology startups, most often at Funding Round and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Partisan Management Group invest in?
Partisan Management Group typically joins rounds of $6.1M–$30M at Series A and $16M–$50M at Series B. These are whole funding-round sizes, not Partisan Management Group's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Partisan Management Group took part in.
How do I contact Partisan Management Group?
Public channels for Partisan Management Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Partisan Management Group?
The team at Partisan Management Group includes Karen Cassidy (Managing Director) and Norman Weldon (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
